Analysts polled by Capital IQ expected a GAAP loss of $0.51.
Revenue for the quarter was $6.95 million, up from $5.01 million a year ago.
Analysts expected $2.4 million.
The company said it expects to file an investigational new drug application for AAV-GAD for the treatment of Parkinson's disease during Q4 2021.
MeiraGTx plans to start later stage clinical studies for AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia in 2022 with Janssen
A phase 3 trial of AAV-RPE65 for patients with RPE65-associated retinal dystrophy is slated for early 2022.
Price: 20.10, Change: -0.05, Percent Change: -0.25
|Marcus & Millichap Unit Brokers $96 Million Sale of ...|
|RenaissanceRe Holdings Files for Up to $1 Billion Mi...|
|Armstrong Flooring Secures Bankruptcy Court Approval...|
|Baudax Bio Launches $2 Million Registered Direct Off...|
|--Foot Locker Maintains Dividend at $0.40/Share; Pay...|